Recap: Amicus Therapeutics Q1 Earnings

 

Shares of Amicus Therapeutics FOLD rose 0.6% in pre-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share were up 28.57% over the past year to ($0.25), which missed the estimate of ($0.24).

Revenue of $66,402,000 rose by 9.71% from the same period last year, which missed the estimate of $71,650,000.

Guidance

The upcoming fiscal year's revenue expected to be between $300,000,000 and $315,000,000.

How To Listen To The Conference Call

Date: May 10, 2021

Time: 08:30 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/ivyxswbx

Technicals

52-week high: $25.39

52-week low: $8.83

Price action over last quarter: down 12.18%

Company Overview

Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!